Brian Skorney

In this discussion, guests Brian Skorney, a senior research analyst at Baird, Ned Sharpless, former acting FDA commissioner, and Robert Califf, former FDA commissioner, delve into the impact of Vinay Prasad's departure from the FDA. They examine the political turbulence influencing FDA operations and the biotech sector, especially regarding drug approvals and leadership changes. The conversation highlights the challenges of regulatory integrity, the evolving landscape of gene therapies, and the urgent need for improved data collection in post-marketing drug safety.

Brian Skorney, a senior biotech analyst at Baird, dives into the latest trends from San Francisco Healthcare Week. He highlights Biohaven's innovative degrader platform and its potential impact on IGAN treatment. Skorney also discusses Xenon's KV7 program, emphasizing its promising efficacy in seizure management. He identifies Biogen as a key player due to its advancements in blood biomarkers and dosing methods. Lastly, he reviews the ongoing developments at Sarepta and their gene therapy strategies. Tune in for insightful market perspectives!

Lizzy Lawrence, STAT’s FDA reporter, joins biotech experts Brian Skorney and Daphne Zohar to discuss the impact of a potential Trump presidency on the FDA and the biotech industry. They delve into concerns over regulatory changes, FDA leadership stability, and investor sentiments regarding vaccines and antivirals. The conversation also explores how immigration policies may affect talent acquisition in biotech. Finally, they analyze the Inflation Reduction Act’s effects on drug development and pricing, shedding light on innovation in a politically charged landscape.